Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -23.80% is 78% above its 3-year average of -108.30%, near the high end of its 3-year range (-246.31%–-19.85%).
0.89% below its 12-month average of -23.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.57%.
RETURN ON ASSETS (ROA)
-23.80%
RETURN ON ASSETS (ROA) AVG TTM
-23.59%
RETURN ON ASSETS (ROA) AVG 3Y
-108.30%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-0.89%
CURRENT VS 3Y AVG
+78.02%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.29%
median of 683 covered companies
CURRENT VS SECTOR MEDIAN
+21.43%
vs the sector median at left
BioAge Labs Inc.
Market Cap
$237.38M
Return on Assets (ROA)
-23.80%
TTM Avg
-23.59%
3Y Avg
-108.30%
5Y Avg
N/A
Market Cap
$237.69M
Return on Assets (ROA)
-8.99%
TTM Avg
-7.90%
3Y Avg
-14.69%
5Y Avg
-13.78%
Market Cap
$235.50M
Return on Assets (ROA)
-4.22%
TTM Avg
-27.32%
3Y Avg
-24.76%
5Y Avg
-32.27%
Market Cap
$240.97M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$240.98M
Return on Assets (ROA)
-8.48%
TTM Avg
-16.43%
3Y Avg
-20.20%
5Y Avg
-32.31%
Market Cap
$241.56M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$242.35M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$243.62M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$246.67M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $237.38M | -23.80% | -23.59% | -108.30% | N/A |
| High Tide Inc. (HITI)vs › | $237.69M | -8.99% | -7.90% | -14.69% | -13.78% |
| MacroGenics, Inc. (MGNX)vs › | $235.50M | -4.22% | -27.32% | -24.76% | -32.27% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.97M | -114.79% | -67.19% | -63.94% | -45.91% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.98M | -8.48% | -16.43% | -20.20% | -32.31% |
| InflaRx N.V. (IFRX)vs › | $241.56M | -23.88% | -71.64% | -51.89% | -47.09% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | -187.80% | -213.40% | -188.65% | -151.14% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.62M | N/A | -14.72% | -16.00% | -18.82% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $246.67M | -244.25% | -369.36% | -230.97% | -157.86% |
| Biodesix, Inc. (BDSX)vs › | $231.59M | -29.12% | -42.23% | -51.88% | -48.35% |
ROA
-23.8%
ROE
-25.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -27.33% |
| 2024-12-31 | -19.85% |
| 2023-12-31 | -246.31% |
| 2022-12-31 | -139.72% |
